10/26/09 President Obama Declares National Emergency
CNN Reports President Obama Declares National Emergency To Deal
With The "Rapid Increase In Illness" From The H1N1 Influenza Virus;
Cannabis Science Continues Progress On Its Research To Show Cannabis
Can Reduce Risk of Death from "Swine Flu"
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical
cannabis company, is urging that US government recognize that
phytocannabinoid pharmaceutical products can help reduce Adult
Respiratory Distress Syndrome (ARDS)-associated deaths from both the
Avian and Swine Influenza infections, as President Obama declares a
national emergency. President Obama signed the declaration late Friday
and announced it Saturday. We urge readers go to: http://www.cnn.com/2009/HEALTH/10/24/h1n1.obama/index.html
to read the whole story on the CNN website.
President Obama stated, "The 2009 H1N1 pandemic continues to evolve. The
rates of illness continue to rise rapidly within many communities across
the nation, and the potential exists for the pandemic to overburden
health care resources in some localities."
President Obama continued with, "Thus, in recognition of the continuing
progression of the pandemic, and in further preparation as a nation, we
are taking additional steps to facilitate our response."
Cannabis Science, Inc. President & CEO Dr. Robert Melamede stated,
“Clearly, there is little time to gear up the mass production of
pharmaceutical cannabis products to meet the immediate needs of this
national emergency. However, President Obama’s new policy of federal
tolerance of medical marijuana where is it legal under state laws, makes
it possible for Cannabis Science to work with the medical marijuana
patients and providers in some states to help develop products to meet
patients’ needs. If the situation is dire enough to justify calling it a
“National Emergency”, then surely medical ethics require that we work
diligently with all relevant research.”
Dr. Melamede also deplored efforts in Los Angeles and other areas to
close dispensaries and/or ban edibles. “It is hard to imagine a more
wrong-headed approach or a worse time to deprive people of access to
cannabis edibles. Again, we recommend, based on sound scientific
principles, that medical marijuana users should switch to edibles if
they come down with an influenza infection. We believe that the
irritation associated with the pulmonary route, when a person has an
influenza infection, may lead to unnecessary deaths. In contrast, oral
administration may prevent many deaths. We hope that due to the
magnitude of this pandemic threat, that the FDA will fast track our
proposal."
Please visit our website http://www.cannabisscience.com
in the next few days as we will be posting a survey for those who
encountered the H1N1 and other influenza symptoms and experiences. This
Cannabis Science Survey will be designed to acquire anecdotal human data
regarding the effects of Medical Marijuana on influenza infections. The
company plans to monitor activity, collect data, and report findings in
its reports to the FDA.
Cannabis Science H1N1 Swine Flu Formulation:
Dr. Melamede explains, “We now know that the endocannabinoid system
plays a critical role in maintaining human health. The human body
produces Endocannabinoids on demand when they are needed. They help
restore homeostasis (biochemical balance). The Cannabis plant produces
Phytocannabinoids. When the human body has endocannabinoid deficiencies,
it cannot effectively restore the healthy biochemical state needed to
counter a particular illness. Phytocannabinoids from the Cannabis plant
can replace the deficient endocannabinoid activity in the human body to
restore a health-promoting level of cannabinoid activity. Cannabis
Science will test its pharmaceutical products with FDA guidance and
oversight to determine if it will reduce ARDS-associated deaths from
both the Avian and Swine influenza infections.”
This Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Act of 1934. A statement containing works such as
"anticipate," "seek," intend," "believe," "plan," "estimate," "expect,"
"project," "plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results anticipated by
these forward-looking statements may not occur. Factors that could cause
or contribute to such differences include the future U.S. and global
economies, the impact of competition, and the Company's reliance on
existing regulations regarding the use and development of cannabis-based
drugs. Cannabis Science, Inc. does not undertake any duty nor does it
intend to update the results of these forward-looking statements.
Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede, 888-889-0888
President & CEO
\n info@cannabisscience.com
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
http://www.cannabisscience.com
or
Peter Glaser, 954-687-3717
Investor Relations
\n info@cannabisscience.com
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Comments